News & Updates

The overall survival (OS) benefit observed with the STRIDE regimen compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) is consistent regardless of baseline liver function, according to exploratory analysis of data from the phase III HIMALAYA trial presented at ESMO GI 2022.

The use of spleen pull-out lymph node dissection in the splenic hilum is both safe and feasible for patients with gastric cancer undergoing radical gastrectomy, a recent study has found.

Low serum albumin levels appear to be an important risk factor for poor survival outcomes among patients with metastatic cervical cancer, a recent study has found.

In patients with metastatic colorectal cancer (mCRC), using trifluridine/tipiracil with bevacizumab is a safe and effective treatment for refractory disease, a recent study has found.

Individuals exposed to low-dose methotrexate risk developing melanoma, although the absolute risk increase remains very low, as shown in a recent meta-analysis.

Gastric cancer (GC) patients show an altered metabolic profile as compared with healthy individuals, a recent China study has found. A biomarker panel monitoring for nine metabolites can facilitate timely detection of GC.

First-line treatment of ALK-positive non-small-cell lung cancer (NSCLC) with lorlatinib improves progression-free survival (PFS) and reduces central nervous system (CNS) progression vs crizotinib, regardless of presence or absence of baseline brain metastases (BM), a post hoc analysis of the phase III CROWN trial has shown.

A recent first-in-human study has shown that directly applying pembrolizumab to the bladder is a safe and effective treatment option for patients with nonmuscle-invasive bladder cancer (NMIBC) who are unresponsive to bacillus Calmette-Guérin (BCG) treatment.